share_log

Mangoceuticals | POS AM: Post-effective amendment to a registration statement that is not immediately effective upon filing

Mangoceuticals | POS AM: Post-effective amendment to a registration statement that is not immediately effective upon filing

Mangoceuticals | POS AM：修改註冊聲明表
美股SEC公告 ·  07/26 08:03
Moomoo AI 已提取核心訊息
Mangoceuticals, Inc., a Texas-based pharmaceutical company, has filed a post-effective amendment with the Securities and Exchange Commission (SEC) on July 26, 2024, to deregister 13,220,829 unsold shares of common stock. These shares were initially registered for sale and issuable upon the conversion of 500 shares of Series B Convertible Preferred Stock as part of a previous registration statement (No. 333-278888) declared effective on May 9, 2024. The deregistration follows the full conversion of all 500 shares of Series B Preferred Stock into 2,493,997 shares of common stock, received by the selling stockholder as of July 25, 2024. No additional securities are being deregistered at this time. The company's CEO, Jacob D. Cohen, has signed off on the amendment.
Mangoceuticals, Inc., a Texas-based pharmaceutical company, has filed a post-effective amendment with the Securities and Exchange Commission (SEC) on July 26, 2024, to deregister 13,220,829 unsold shares of common stock. These shares were initially registered for sale and issuable upon the conversion of 500 shares of Series B Convertible Preferred Stock as part of a previous registration statement (No. 333-278888) declared effective on May 9, 2024. The deregistration follows the full conversion of all 500 shares of Series B Preferred Stock into 2,493,997 shares of common stock, received by the selling stockholder as of July 25, 2024. No additional securities are being deregistered at this time. The company's CEO, Jacob D. Cohen, has signed off on the amendment.
總部位於德克薩斯州的藥品公司Mangoceuticals，Inc.於2024年7月26日向證券交易委員會（SEC）提交了一份後效修正案，以註銷13220829股未售出的普通股。這些股票最初註冊出售，並可在之前的註冊聲明（No.333-278888）於2024年5月9日發效時轉換爲500股B系列可轉換優先股的一部分。註銷程序之後，所有500股B系列優先股均已完全轉換爲2493997股普通股，並於2024年7月25日被售賣股東收到。目前沒有其他證券被註銷。該公司首席執行官Jacob D. Cohen已經簽署了修正案。
總部位於德克薩斯州的藥品公司Mangoceuticals，Inc.於2024年7月26日向證券交易委員會（SEC）提交了一份後效修正案，以註銷13220829股未售出的普通股。這些股票最初註冊出售，並可在之前的註冊聲明（No.333-278888）於2024年5月9日發效時轉換爲500股B系列可轉換優先股的一部分。註銷程序之後，所有500股B系列優先股均已完全轉換爲2493997股普通股，並於2024年7月25日被售賣股東收到。目前沒有其他證券被註銷。該公司首席執行官Jacob D. Cohen已經簽署了修正案。
有用
沒用

該公告為獨立文件：

獨立文件1  查看翻譯

声明：本內容僅用作提供資訊及教育之目的，不構成對任何特定投資或投資策略的推薦或認可。 更多信息